Form D · Biotechnology
Evogen, Inc.
Lenexa, KS · CIK 0001170875
Offering snapshot reported Feb 19, 2014 · SEC filing
- Reported sold
- $852K Offering amount: $1.58M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 21, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 19, 2014 | Initial | $852,420 | No comparison | 8 | SEC filing |
| Jan 25, 2010 | Initial | $1,041,322 | No comparison | 10 | SEC filing |
| May 7, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-212167
Source: Form D, filed Feb 19, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Dondes | Executive |
| Thomas Jantsch | Director, Executive |
| Hans Kastensmith | Director, Executive, Promoter |
| Nathan Ledeboer | Director |
| Jonathan Leitersdorf | Director |
| John Levy | Director |
| Sean Reineke | Director |
| James Spigarelli | Director |
| Richard St. Clair | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10513 W. 84th Terrace
Lenexa, KS, 64214
Lenexa, KS, 64214